CASE REPORT

Fatal Thrombotic Microangiopathy and Posterior Reversible Encephalopathy Syndrome in a Patient with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Dermatomyositis

Shotaro Yamamoto, Takao Nagashima, Yoichiro Akiyama, Katsuya Nagatani, Masahiro Iwamoto and Seiji Minota

Abstract:
A 56-year-old woman presented with dermatomyositis positive for anti-melanoma differentiation-associated gene 5 antibody. No interstitial lung disease was detected. Despite treatment with methylprednisolone pulse therapy and cyclosporine, dysphagia developed. Furthermore, the presence of thrombocytopenia, elevated lactate dehydrogenase levels, and an undetectable haptoglobin level suggested the possibility of thrombotic microangiopathy (TMA). Disturbed consciousness developed shortly after TMA onset, and brain magnetic resonance imaging revealed hyperintensity lesions in the bilateral basal ganglia, thalami, and brainstem. The patient was diagnosed with atypical posterior leukoencephalopathy syndrome before dying of heart failure later that day. In conclusion, early TMA recognition and prompt intensive treatment are critical in such cases.

Key words: hemophagocytic syndrome, hemophagocytic lymphohistiocytosis, interstitial lung disease, thrombotic thrombocytopenic purpura

(Intern Med 60: 3329-3333, 2021)
(DOI: 10.2169/internalmedicine.7309-21)

Introduction

Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody-positive dermatomyositis (DM) accounts for 11-60% of cases of DM in Asian patients. Among such patients, more than 90% also suffer from interstitial lung disease (ILD), which follows a rapidly progressive course in 33-71% of patients. Furthermore, approximately half of all cases of ILD result in death (1-5). Intensive immunosuppressive therapy consisting of a combination of glucocorticoids, cyclophosphamide, and calcineurin inhibitors (CNIs) is typically required to treat rapidly progressive ILD (6).

Posterior reversible encephalopathy syndrome (PRES) is a neurological disorder characterized by various neurological symptoms, including headache, loss of vision, seizure, mental disorder, disturbance of consciousness, and focal neurological symptoms (7, 8). During neuroimaging, patients with PRES typically show reversible brain edema in the bilateral parieto-occipital regions as well as the posterior frontal, temporal, cerebellar, basal ganglia, and brainstem locations (8). While connective tissue diseases, such as systemic lupus erythematosus (SLE), vasculitis, systemic sclerosis, and Sjögren’s syndrome, can cause PRES, DM is rarely the underlying condition (8-10).

Thrombotic thrombocytopenic purpura (TTP), a phenotype of thrombotic microangiopathy (TMA), is a potential cause of PRES (11, 12). Furthermore, connective tissue diseases are recognized as a cause of secondary TMA. Although rare, there have been reports of patients with both DM and TMA (13).

We herein report a patient with DM who was positive for anti-MDA5 antibody and complicated with both fatal TMA and PRES.

Case Report

A 56-year-old woman was transferred to our hospital for
Computed tomography (CT) of the chest revealed no ILD. Transthoracic echocardiography showed a slightly reduced left ventricular function (ejection fraction, 53%). Short tau inversion recovery images taken during magnetic resonance imaging (MRI) of the thighs indicated the presence of a high-intensity lesion in the quadriceps femoris and biceps femoris muscles. Despite the previously given diagnosis of DM, a biopsy of the quadriceps femoris muscle did not reveal any myositis.

We began treatment with intravenous methylprednisolone (mPSL) pulse therapy (1 g/day for 3 days) followed by oral PSL and cyclosporine (CyA) doses of 40 mg/day (1 mg/kg) and 120 mg/day (3 mg/kg), respectively (Fig. 2). Although the serum ferritin and liver enzymes decreased, the platelet count also decreased sequentially, and myalgia continued. As the trough level of CyA was low (53 ng/mL), the dose was increased to 160 mg/day (4 mg/kg). On the 18th day after admission, we switched from oral administration of PSL and CyA to intravenous administration upon detecting worsening symptoms of dysphagia in the patient. On the 19th day, the oxygen saturation suddenly decreased to 90%. Chest CT revealed bilateral dorsal lung infiltration, suggesting either aspiration pneumonia or the emergence of ILD. KL-6 conversely decreased to 946 U/mL. The diagnosis of TMA was given based on the findings of thrombocytopenia, elevated LDH levels, and an undetectable serum level of haptoglobin.

We proposed a treatment with plasmapheresis, but the patient refused. Treatment with intravenous ampicillin/sulbactam (12 g/day) was initiated, after which intravenous cyclophosphamide (IVCY, 0.9 g, 0.75 g/m²) was added to the treatment regimen. On the 21st day, the patient developed disturbance of consciousness, atrial fibrillation, and tachypnea. Serum ferritin and LDH levels further increased (7,667 ng/mL and 1,180 U/L, respectively), hemoglobin and platelet counts decreased (7.7 g/dL and 1.1×10⁴/μL, respectively), and erythrocyte fragmentation was detected. CyA administration was discontinued as the trough level of CyA increased to 494 ng/mL. T2-weighted and fluid-attenuated inversion recovery images taken during brain MRI revealed high-intensity lesions in the bilateral basal ganglia, thalamus, and brainstem (Fig. 3). Although the patient’s blood pressure was nearly normal (systolic pressure of approximately 140 mmHg), the diagnosis of PRES was made, and another intravenous mPSL pulse was added to the treatment regimen. However, hypotension developed shortly after the pulse was administered. Transthoracic echocardiography revealed generalized myocardial hypomotility (ejection fraction, 30%) with asynergy of the anterior wall. The serum troponin T level was slightly elevated at 0.04 ng/mL (normal range, <0.014).

Despite vasopressor therapy, the patient died a few hours later. Autopsy imaging using CT revealed no cerebral hemorrhage or infarction. The activity level of a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13 (ADAMTS13) was found to be normal, and
Discussion

We herein report a patient with DM who was positive for anti-MDA5 antibody and developed TMA and PRES during intensive treatment. MRI revealed brain edema in the basal ganglia, thalami, and brainstem, which are atypical regions for PRES. The condition of the patient deteriorated rapidly after the development of TMA, resulting in death by heart failure shortly after the diagnosis of PRES was made.

Cases of DM complicated by PRES are rarely reported in the literature (10). We speculated that TMA was the most likely cause of PRES in the present case, as TMA was diagnosed shortly before the development of PRES. Previous reports of patients with SLE found that TMA, hemolytic anemia, and thrombocytopenia often coexisted once PRES began to develop (14). CyA has also been found to be a risk factor for PRES, but the incidence of PRES is reported to be less than 1% in patients undergoing organ transplantation (15, 16). However, CyA could not be ruled out as a causative drug, as PRES has been found to develop, irrespective of trough CyA levels (7, 16). Although cyclophosphamide has been reported as a rare cause of PRES, it is difficult to confirm the presence of a cause-and-effect relationship due to the implication of numerous other risk factors, such as renal involvement, hypertension, the use of glucocorticoids or other drugs, and underlying disease activity (17).

TMA is a rare complication of myositis that tends to develop when the disease activity of myositis is high (13). Similarly, the disease activity was elevated in our patient, as the serum ferritin levels increased along with the development of TMA. Previous studies have suggested that a correlation exists between serum ferritin levels and disease activity in patients positive for anti-MDA5 antibody (1). Although CNI is a potential cause of TMA, this association has only been reported in 0.12-3.3% of patients undergoing organ transplantation (18, 19). Thus, it seems unlikely that CyA was the cause of TMA in our patient. However, in cases where TMA is suspected, whether or not CNIs should be discontinued requires careful consideration. Although the activity of ADAMTS13 was found to be normal in the present patient, normal or subnormal levels of activity are often observed in patients with TMA associated with connective tissue disease.
tissue diseases, including DM (20).

The brain edema observed in the basal ganglia, thalami, and brainstem in the present case was atypical for PRES. Although the posterior portion of the parietal and occipital lobes are commonly involved in typical PRES, 2-6% of patients with PRES lack lesions in these areas (8, 21). These atypical patterns are referred to as “central-variant” PRES (22) and may be related to TTP or treatment with CyA (11, 22, 23). We were unable to confirm the reversibility of the brain edema in this case, as the patient died shortly after the diagnosis of PRES. However, no cerebral hemorrhaging or infarction was observed during autopsy imaging. Thus, the diagnosis of PRES may have been inappropriate.

Myocardial involvement was the most probable direct cause of death in this patient, as echocardiography revealed generalized myocardial hypomotility with asynergy. Cardiac manifestations of TTP vary widely, with prior research reporting symptoms such as asymptomatic elevation of cardiac biomarkers, chest pains, arrhythmias, heart failure, myocardial infarction, and even sudden cardiac death (24). Among patients with myositis complicated by TMA, heart failure was found to be the cause of death in 3 out of 13 patients (13). However, the heart failure may have been an inherent manifestation of DM (25). Heart involvement is also common in patients with lupus as well as TMA (26). The prognosis also appears to be poor in patients with SLE who develop TMA and PRES (14).

In conclusion, we encountered a patient with anti-MDA5 antibody-positive DM complicated by both TMA and PRES. In addition to the finding of rapidly progressive ILD, the patient’s TMA may have been a fatal complication of the anti-MDA5 antibody-positive DM observed in this case. If either TMA or PRES develops during the treatment of DM, it is critical to determine whether the complication is drug-induced or a consequence of the disease activity of DM per se. However, given the difficulty in discriminating these pathologies, the early recognition of TMA and prompt intensive treatment including plasmapheresis is critical.

The authors state that they have no Conflict of Interest (COI).

References

1. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440, 2010.
2. Hamaguchi Y, Kuwana M, Hoshino K, et al. Clinical correlations with dermatomyositis-specific autoantibodies in adult Japanese patients with dermatomyositis: a multicenter cross-sectional study. Arch Dermatol 147: 391-398, 2011.
3. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51: 1278-1284, 2012.
4. Chen Z, Cao M, Plana MN, et al. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease; a review of the literature and a meta-analysis. Arthritis Care Res (Hoboken) 65: 1316-1324, 2013.
5. Tanizawa K, Handa T, Nakashima R, et al. The prognostic value of HRCT in dermatomyositis-associated interstitial lung disease. Respir Med 107: 745-752, 2013.
6. Kawasumi H, Gono T, Kagawuchi Y, Yamanaka H. Recent treatment of interstitial lung disease with idiopathic inflammatory myopathies. Clin Med Insights Circ Respir Pulm Med 9: 9-17, 2015.
7. Hinchei J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 334: 494-500, 1996.
8. Fugate JE, Claassen DO, Cloft HJ, Callmes DF, Kozak OS, Rabinstein AA. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc 85: 427-432, 2010.
9. Dhillon A, Velazquez C, Siva C. Rheumatologic diseases and posterior reversible encephalopathy syndrome: two case reports and review of the literature. Rheumatol Int 32: 3707-3713, 2012.
10. Zhu YY, Wang J, Wu YB, Ma Y. Reversible posterior leukoen cephalopathy syndrome in a patient with dermatomyositis. Int Med J 22: 53-55, 2015.
11. Burrus TM, Wijdicks EF, Rabinstein AA. Brain lesions are most often reversible in acute thrombotic thrombocytopenic purpura. Neurology 73: 66-70, 2009.
12. Makranz C, Khutsurauli S, Kalish Y, et al. Neurological variability in chemotheraphy-induced posterior reversible encephalopathy syndrome associated with thrombotic microangiopathy: case reports and literature review. Mol Clin Oncol 8: 178-182, 2018.
13. Yamada S, Yamashita H, Nakano M, et al. Thrombotic microangiopathy with polymyositis/dermatomyositis: three case reports and a literature review. Intern Med 57: 2259-2265, 2018.
14. Lai CC, Chen WS, Chang YS, et al. Clinical features and outcomes of posterior reversible encephalopathy syndrome in patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 65: 1766-1774, 2013.
15. Bartynski WS, Tan HP, Boardman JF, Shapiro R, Marsh JW. Posterior reversible encephalopathy syndrome after solid organ transplantation. AJNR Am J Neuroradiol 29: 924-930, 2008.
16. Song T, Rao Z, Tan Q, et al. Calcineurin inhibitors associated posterior reversible encephalopathy syndrome in solid organ transplantation: report of 2 cases and literature review. Medicine (Baltimore) 95: e3173, 2016.
17. Zekic T, Benic MS, Antulov I, Antonic I, Novak S. The multifactorial origin of posterior reversible encephalopathy syndrome in cyclophosphamide-treated lupus patients. Rheumatol Int 37: 2105-2114, 2017.
18. Sarkodee-Adoo C, Sotirescu D, Sensenbrenner L, et al. Thrombotic microangiopathy in blood and marrow transplant patients receiving tacrolimus or cyclosporine A. Transfusion 43: 78-84, 2003.
19. Bren A, Pajek J, Grego K, et al. Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy. Transplant Prog 37: 1889-1891, 2005.
20. Matsuyama T, Kuwana M, Matsumoto M, Isonishi A, Inokuma S, Fujimura Y. Heterogeneous pathogenic processes of thrombotic microangiopathies in patients with connective tissue diseases. Thromb Haemost 96: 533-539, 2006.
21. Bartynski WS, Boardman JF. Distinct imaging patterns and lesion distribution in posterior reversible encephalopathy syndrome. AJNR Am J Neuroradiol 28: 1310-1327, 2007.
22. McKinney AM, Jagadeesan BD, Truwit CL. Central-variant posterior reversible encephalopathy syndrome: brainstem or basal ganglia involvement lacking cortical or subcortical cerebral edema.
23. Bas DF, Oguz KK, Topcuoglu MA. Atypical reversible posterior leukoencephalopathy syndrome in thrombotic thrombocytopenic purpura. Intern Med 47: 1931-1934, 2008.

24. Wiernek SL, Jiang B, Gustafson GM, Dai X. Cardiac implications of thrombotic thrombocytopenic purpura. World J Cardiol 10: 254-266, 2018.

25. Zhang L, Wang GC, Ma L, Zu N. Cardiac involvement in adult polymyositis or dermatomyositis: a systematic review. Clin Cardiol 35: 686-691, 2012.

26. Hu WX, Liu ZZ, Chen HP, Zhang HT, Li LS, Liu ZH. Clinical characteristics and prognosis of diffuse proliferative lupus nephritis with thrombotic microangiopathy. Lupus 19: 1591-1598, 2010.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).